Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 10, 2012, Pages 1628-1634

  Buvat, Irène ^a   Necib, Hatem ^a   Garcia, Camilo ^b   Wagner, Antoine ^b   Vanderlinden, Bruno ^b   Emonts, Patrick ^b   Hendlisz, Alain ^b   Flamen, Patrick ^b  

^a Centre National de la Recherche Scientifique   (France)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Advanced colorectal cancer; EORTC criteria; FDG; Objective response prediction; PET CT; SUV

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BODY SURFACE; BODY WEIGHT; CANCER PATIENT; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; HUMAN; METASTASIS; METASTATIC COLORECTAL CANCER; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84868201624     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2172-2     Document Type: Article

References (19)

1. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
2. Hoekstra OS, van Lingen A, Ossenkoppele GJ, Golding R, Teule GJ. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med 1993;20:1214-7.
3. Weber WA. Assessing tumor response to therapy. J Nucl Med 2009;50:1S-10S.
4. Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL, et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007;11:961-9.
5. Lin C, Itti E, Haioun C, Petegrief Y, Luciani A, Dupuls J, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626-32.
6. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006;47:1059-66.
7. Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignand M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009;14:30-40.
8. Wahl R, Jacene H, Kasamon Y, Lodge M. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-50.
9. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50:11S-20S.
10. Scheuermann JS, Saffer JR, Karp JS, Levering AM, Siegel BA. Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med 2009;50:1187-93.
11. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
12. Hendlisz A, Emonts P, Covas A, Ameye L, Paesmans M, Castany Prado Maria del Rosario R, et al. Is positron emission tomography (PET) with FDG an early predictor of the RECIST morphological response to chemotherapy in metastatic colorectal cancer patients (mCRC)? J Clin Oncol 2009;27:15s.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
14. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996;17:890-4.
15. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
16. Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, et al. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol 2012. doi:10.1093/annonc/ mdr554.
17. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008;19:348-52.
18. de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592-8.
19. Necib H, Garcia C, Wagner A, Vanderlinden B, Emonts P, Hendlisz A, et al.Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging. J Nucl Med 2011;52:354-61.